Claims for Patent: 8,999,953

Summary for Patent: 8,999,953

Title:	Cyclodextrin nanotechnology for ophthalmic drug delivery
Abstract:	The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.
Inventor(s):	Loftsson; Thorsteinn (Reykjavik, IS), Stefansson; Einar (Reykjavik, IS)
Assignee:	Oculis EHF (Reykjavik, IS)
Application Number:	14/106,265
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,999,953
Patent Claims:	1. A method for the treatment of a condition of the posterior segment and/or the anterior segment of the eye comprising applying topically to the eye surface of a subject in need of such treatment, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 5% (w/v) to about 50% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 50% (w/v) to about 95% (w/v) of the drug as solid drug/cyclodextrin complex particles, the size of the particles in the solid phase being from about 0.1 .mu.m to about 500 .mu.m, the drug/cyclodextrin complex particles being capable of dissolving in tear fluid, the cyclodextrin comprising at least one natural cyclodextrin selected from the group consisting of .alpha.-cyclodextrin, .beta.-cyclodextrin and .gamma.-cyclodextrin, the total concentration of the drug/cyclodextrin complex in the composition being above the aqueous solubility of the complex. 2. The method according to claim 1, wherein the drug is a corticosteroid and the condition is a disease of the retina and/or optic nerve which is responsive to treatment with a corticosteroid; or wherein the drug is a carbonic anhydrase inhibitor and the condition is a disease of the retina and/or optic nerve which is responsive to treatment with a carbonic anhydrase inhibitor; or wherein the drug is a GABA agonist and the condition is a disease of the retina which is responsive to treatment with a GABA agonist; or wherein the condition is age-related macular degeneration and the drug is AG013958, triamcinolone acetonide, ranibizumab, macugen or sham. 3. The method according to claim 1, wherein the drug is an antibiotic and the condition is a bacterial eye infection; or wherein the drug is an antiviral agent and the condition is a viral eye infection. 4. The method according to claim 1, wherein the composition is in the form of eye drops, an eye mist or an eye gel. 5. The method according to claim 1, wherein the composition comprises from about 0.25% to about 40% of cyclodextrin, and further comprises up to about 5% (w/v) of water-soluble polymer, up to about 5% (w/v) of metal salts and up to about 5% (w/v) of organic salts, and optionally further comprises at least one buffer salt and/or at least one preservative. 6. The method according to claim 1, wherein the composition comprises from about 2%(w/v) to about 20% (w/v) of cyclodextrin, and further comprises from about 0.1% (w/v) to about 1% (w/v) of water-soluble polymer, up to about 2% (w/v) of metal salts and up to about 3% (w/v) of organic salts, and optionally further comprises at least one buffer salt and/or at least one preservative. 7. The method according to claim 5, wherein the metal salt has a divalent or trivalent cation and/or wherein the organic salt is a salt of or an ionized form of acetic acid, glutaric acid, a hydroxy acid or an amino acid. 8. The method according to claim 5, wherein the metal salt is a magnesium salt and/or wherein the organic salt is a salt of or the ionized form of citric acid, lactic acid, ascorbic acid, tartaric acid or lysine. 9. The method according to claim 7, wherein said magnesium salt is magnesium chloride. 10. The method according to claim 1, wherein the drug/cyclodextrin particles dissolve within from about 10 minutes to about 24 hours alter administration to the eye surface. 11. The method according to claim 1, wherein the cyclodextrin further comprises at least one pharmaceutically acceptable cyclodextrin derivative selected from the group consisting of hydroxyalkyl-.beta.-cyclodextrins, hydroxyalkyl-.gamma.-cyclodextrins, randomly methylated-.beta.-cyclodextrin, .beta.-cyclodextrin sulfobutyl ether, .gamma.-cyclodextrin sulfobutyl ether, branched .beta.-cyclodextrin and branched .gamma.-cyclodextrins. 12. The method according to claim 11, wherein the at least one pharmaceutically acceptable cyclodextrin derivative is hydroxypropyl-.beta.-cyclodextrin, hydroxypropyl-.gamma.-cyclodextrin, randomly methylated .beta.-cyclodextrin, .beta.-cyclodextrin sulfobutyl ether, .gamma.-cyclodextrin sulfobutyl ether or glucosyl-.beta.-cyclodextrin. 13. The method according to claim 1, wherein the cyclodextrin comprises at least .gamma.-cyclodextrin and/or wherein the cyclodextrin further comprises at least hydroxypropyl-.gamma.-cyclodextrin. 14. The method according to claim 5, wherein said polymer is methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethylcellulose, polyvinyl alcohol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide or chitosan. 15. The method according to claim 2, wherein said GABA agonist is a benzodiazepine. 16. The method according to claim 2, wherein said carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxyzolamide or brinzolamide; or wherein said corticosteroid is dexamethasone, hydrocortisone, triamcinolone, triamcinolone acetonide, prednisolone, fluorometholone, medrysone, rimexolone, loteprednol etabonate or etiprednol dicloacetate; or wherein said GABA agonist is baclofen, tiagabine, valproic acid, progabide, muscimol, etomidate, propofol, diazepam, alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, mebazepam, nitrazepam, oxazepam, medazepam, lorazepam, prazepam, quazepam, triazolam, temezepam or lorazolam. 17. The method according to claim 1, wherein said cyclodextrin is a mixture of a natural .alpha.-, .beta.- or .gamma.-cyclodextrin and the corresponding water-soluble .alpha.-, .beta.- or .gamma.-cyclodextrin derivative selected from the group consisting of hydroxyalkyl-.beta.-cyclodextrins, hydroxyalkyl-.gamma.-cyclodextrins, randomly methylated .beta.-cyclodextrin, the sulfobutyl ether of .beta.-cyclodextrin, the sulfobutyl ether of .gamma.-cyclodextrin, branched .beta.-cyclodextrins and branched .gamma.-cyclodextrins. 18. The method according to claim 17, wherein said water-soluble derivative is selected from the group consisting of hydroxypropyl-.beta.-cyclodextrin, hydroxypropyl-.gamma.-cyclodextrin, randomly methylated .beta.-cyclodextrin, the sulfobutyl ether of .beta.-cyclodextrin, the sulfobutyl ether of .gamma.-cyclodextrin, glucosyl .beta.-cyclodextrin and glucosyl .gamma.-cyclodextrin. 19. The method according to claim 17, wherein said cyclodextrin is a mixture of .gamma.-cyclodextrin and 2-hydroxypropyl-.gamma.-cyclodextrin, or a mixture of .gamma.-cyclodextrin and the sulfobutyl ether of .gamma.-cyclodextrin, or a mixture of .beta.-cyclodextrin and 2-hydroxypropyl-.beta.-cyclodextrin, or a mixture of .beta.-cyclodextrin and the sulfobutyl ether of .beta.-cyclodextrin, or a mixture of .beta.-cyclodextrin and randomly methylated .beta.-cyclodextrin. 20. The method according to claim 1, wherein the drug is AG013958, triamcinolone acetonide, ranibizumab, macugen or sham, said composition being in the form of eye drops.

Details for Patent 8,999,953

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2025-07-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2025-07-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2025-07-22